Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

Sunday, August 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals presented new data at the ESC Congress 2026, highlighting the effectiveness of RNAi-powered silencing in treating cardiovascular diseases. The results strengthen the clinical profile of AMVUTTRA® (vutrisiran) in various patient populations and treatment settings for transthyretin amyloidosis (ATTR). This reinforces the drug's potential across different manifestations of the disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data reinforces efficacy of RNAi-powered silencing.
  • Strength of AMVUTTRA® demonstrated across various ATTR patient populations.
  • Positive implications for treatment settings and disease manifestations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
1.9%
average across 8 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data ex

Frequently Asked Questions

What was presented at the ESC Congress 2026?

Alnylam presented new data on RNAi-powered silencing for cardiovascular disease.

What is AMVUTTRA® used for?

AMVUTTRA® (vutrisiran) is used for treating transthyretin amyloidosis (ATTR).

What does the new data reinforce?

The data reinforces the clinical profile of AMVUTTRA® across various ATTR patient populations.

Who is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals is a leading company in RNAi therapeutics.

ShareAdd on Google
Tags: ALNY Viatris Investor Conferences Healthcare Alnylam AMVUTTRA ATTR ESC Congress 2026 vutrisiran
Last updated: Aug 30, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 1
Obese or Overweight Healthy Volunteers →

Catalyst track record

+25%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →